Welcome to our dedicated page for Savara SEC filings (Ticker: SVRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Savara Inc. filings document a clinical-stage biopharmaceutical issuer focused on rare respiratory diseases and its development of molgramostim inhalation solution for autoimmune pulmonary alveolar proteinosis. The record includes Nasdaq-listed common stock disclosures, Regulation FD corporate presentations, clinical and regulatory updates, operating and financial results, and material-event reports tied to business operations.
Recent filings also cover definitive proxy materials, board and compensation matters, shareholder voting matters, lease obligations, and debt arrangements under a loan and security agreement. These disclosures describe Savara's capital structure, financing covenants, material agreements, governance practices and corporate reporting obligations.
Savara Inc. (SVRA) Form 4: The company’s Chief Medical Officer reported equity awards on 10/20/2025. The filing shows an acquisition of 35,000 restricted stock units (RSUs) at a price of $0.00, lifting directly held common shares to 190,000 following the transaction. The RSUs vest in full on 10/17/2027, each converting into one share upon vesting.
Separately, the officer received a stock option for 70,000 shares with an exercise price of $4.11 and an expiration on 10/20/2035. This option vests in sixteen equal quarterly installments beginning 10/17/2025. These are routine compensatory awards and do not indicate open‑market buying or selling.
Savara Inc (SVRA) reported an insider ownership update as its Chief Medical Officer filed a Form 3. The filing lists 155,000 shares of common stock beneficially owned, noted to include RSUs that vest in full on December 4, 2025 (80,000) and December 12, 2026 (75,000), each representing a right to one share upon vesting.
Derivative holdings include stock options for 110,000 shares at $4.13 expiring December 11, 2033, vesting in sixteen equal quarterly installments from December 4, 2023, and options for 175,000 shares at $3.35 expiring December 12, 2034, vesting in sixteen equal quarterly installments from December 12, 2024.
Savara Inc. filed a current report to share that it has updated its corporate investor presentation. The new presentation is available on the Investor Relations section of Savara’s website and is also included as Exhibit 99.1 to this report.
The company notes that the information in the presentation and in Item 7.01 of this report is being "furnished" rather than "filed," meaning it is not subject to the usual liability provisions of the Exchange Act and will not be incorporated into other SEC filings unless specifically referenced. Savara also explains that it has no duty to update the presentation, though it may do so in the future through its website, additional SEC reports, press releases, or other public disclosures.
Frazier-affiliated investment vehicles disclosed shared voting and dispositive power over specified Savara Inc. (SVRA) common stock positions. Frazier Life Sciences Public Fund, L.P. directly holds 6,745,296 shares (3.9%); Frazier Life Sciences Public Overage Fund, L.P. holds 2,889,469 shares (1.7%); Frazier Life Sciences X, L.P. holds 324,346 shares (0.2%); and Frazier Life Sciences XI, L.P. holds 1,503,190 shares (0.9%). These percentages are calculated using 172,836,922 shares outstanding as reported by the issuer. The filing clarifies that certain investment committees act by majority vote and explicitly corrects prior attributions of beneficial ownership to individual committee members.
Savara Inc. reported widening losses as it advances its sole product candidate, MOLBREEVI, an inhaled GM-CSF for autoimmune pulmonary alveolar proteinosis. Net loss was $30.4 million for the quarter and $57.0 million for the six months, up from $22.2 million and $42.6 million a year earlier, driven by higher research-and-development and commercial-preparation costs.
The company holds $17.4 million in cash and $129.0 million in short-term investments (total ~$146.4 million) and states this is sufficient to fund operations for at least the next 12 months. Savara received an FDA Refusal to File for its BLA but says the RTF raised CMC information requests only, not safety or efficacy; the company plans a December resubmission and will request Priority Review. Savara has a $200 million Hercules term loan facility with an initial $30 million draw, conditional future tranches tied to regulatory and revenue milestones and covenanted cash requirements that could restrict liquidity.
Schedule 13G filing for Savara Inc. (SVRA) shows that a group of Venrock Healthcare Capital Partners funds and related managers/individuals has crossed the 5% disclosure threshold.
- Reporting group: Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, and principals Nimish Shah and Bong Y. Koh.
- Aggregate beneficial ownership: 9,021,507 common shares.
- Ownership breakdown: 1,997,410 shares (VHCP III); 199,772 shares (VHCP Co-Investment III); 6,824,325 shares (VHCP EG).
- Percentage of class: 5.2% of Savara’s 172,836,922 outstanding shares (as of 13 May 2025).
- Voting & dispositive power: 0 shares sole; 9,021,507 shares shared—indicating coordinated but passive ownership. Filing is under Rule 13d-1(c), not 13D, so the group states no intent to influence control.
- Date of event triggering filing: 30 June 2025; filing signed 08 July 2025.
The disclosure signals that Venrock, a life-science–focused investor, holds a meaningful but non-controlling position in Savara. Investors often view recognized sector specialists taking a >5% stake as a vote of confidence, yet the filing itself does not imply any change in Savara’s strategy, capital structure, or governance. The stake is passive and therefore has limited immediate operational impact.